Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Eisai to Go Solo on Its 1st ADC after BMS Exits Deal
July 2, 2024
- Moderna Files Spikevax as Booster for Kids Aged 6 Months to 4 Years
July 1, 2024
- Daiichi Sankyo’s ADC Arbitration Win Finalized with No Appeal
July 1, 2024
- Healios Pushes Back Definitive MultiStem Deal with Nobelpharma
July 1, 2024
- Xocova Slashes Risk of Hospitalization in Real-World Setting
July 1, 2024
- EA Pharma Grants Global Rights to IBD Drugs to Ensho
July 1, 2024
- Pfizer, Viatris to Copromote Cibinqo, Litfulo in Japan
July 1, 2024
- Kyowa Kirin Files Pen Version of Lumicef in Japan
July 1, 2024
- Eisai’s Alzheimer’s Med Leqembi Now Available in China
July 1, 2024
- Pfizer Seeks Japan Approval for Ulcerative Colitis Drug
July 1, 2024
- Pfizer Files Hemophilia B Gene Therapy in Japan
July 1, 2024
- Physician Predicts 30-40% Switch Rate for Chugai’s PNH Drug Piasky
June 28, 2024
- Nxera Snags US$10 Million Milestone from AbbVie in Neurology Collab
June 28, 2024
- FDA Snubs Daiichi Sankyo’s HER3 ADC over Third-Party Manufacturing Issue
June 28, 2024
- Takeda Files Alagille Syndrome Drug Maralixibat in Japan
June 28, 2024
- Ayumi Taps Ex-Ferring Japan CEO as New President
June 28, 2024
- Sumitomo Resolved to Revive Business, Optimize Japan Organization: New CEO
June 27, 2024
- Jugo Tsumura to Step Down as Ferring Japan CEO
June 27, 2024
- Takeda Targets 50% Female Ratio for Board of Directors: CEO
June 27, 2024
- Takeda CEO’s Pay Tops 2 Billion Yen in FY2023
June 27, 2024
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…